The trial of the Kovid-19 vaccine, being developed by Oxford University and AstraZeneca plc, had to be stopped after a volunteer in the UK became ill. Now the good news is that its testing will be resumed. A statement from Oxford University has emerged in this regard.

“Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so,” the company said in a statement.

AstraZeneca announced on Wednesday it had “voluntarily paused” its trial of the vaccine developed alongside Oxford University after the volunteer developed an unexplained illness.

An independent committee was drafted in to review safety, in what the company and the World Health Organization described as a routine step.

The committee “has concluded its investigations and recommended to the MHRA that trials in the UK are safe to resume”, AstraZeneca said.

AstraZeneca’s vaccine candidate is one of nine around the world currently in late-stage Phase 3 human trials.

LEAVE A REPLY

Please enter your comment!
Please enter your name here